Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer".
Glenmark Pharmaceuticals Limited Press Release Jul 02 2026
Filed with NSE · · 3 pages · English
Watch Glenmark Pharmaceuticals' latest callGlenmark Pharmaceuticals (NSE:GLENMARK) Q1 2026 Earnings Call · Replay · Aug 3Read the transcript of Glenmark Pharmaceuticals (NSE:GLENMARK) Q1 2026 Earnings CallRelease
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Jun 17 2026
- Glenmark Pharmaceuticals Limited Press Release Jun 11 2026
- Press Release Jun 05 2026
- Press Release May 29 2026
- Press Release May 20 2026
Later from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Jul 06 2026
- Glenmark Pharmaceuticals Limited Press Release Jul 21 2026
- Glenmark Pharmaceuticals Limited Press Release Jul 28 2026
- Glenmark Pharmaceuticals Limited Press Release Jul 31 2026
- Glenmark Pharmaceuticals Limited Press Release Aug 20 2026
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals